These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

485 related items for PubMed ID: 16647758

  • 1. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects.
    Zünkler BJ.
    Pharmacol Ther; 2006 Oct; 112(1):12-37. PubMed ID: 16647758
    [Abstract] [Full Text] [Related]

  • 2. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
    Davie C, Pierre-Valentin J, Pollard C, Standen N, Mitcheson J, Alexander P, Thong B.
    J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
    [Abstract] [Full Text] [Related]

  • 3. QT interval prolongation and cardiac risk assessment for novel drugs.
    Picard S, Lacroix P.
    Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
    [Abstract] [Full Text] [Related]

  • 4. Molecular predictors of drug-induced prolongation of the QT interval.
    Dilaveris PE.
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
    [Abstract] [Full Text] [Related]

  • 5. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
    Finlayson K, Witchel HJ, McCulloch J, Sharkey J.
    Eur J Pharmacol; 2004 Oct 01; 500(1-3):129-42. PubMed ID: 15464027
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the effects of methadone and heroin on human ether-à-go-go-related gene channels.
    Zünkler BJ, Wos-Maganga M.
    Cardiovasc Toxicol; 2010 Sep 01; 10(3):161-5. PubMed ID: 20467834
    [Abstract] [Full Text] [Related]

  • 7. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
    Wang L, Wible BA, Wan X, Ficker E.
    J Pharmacol Exp Ther; 2007 Feb 01; 320(2):525-34. PubMed ID: 17095614
    [Abstract] [Full Text] [Related]

  • 8. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.
    Guthrie H, Livingston FS, Gubler U, Garippa R.
    J Biomol Screen; 2005 Dec 01; 10(8):832-40. PubMed ID: 16234341
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the effects of metoclopramide and domperidone on HERG channels.
    Claassen S, Zünkler BJ.
    Pharmacology; 2005 Apr 01; 74(1):31-6. PubMed ID: 15640612
    [Abstract] [Full Text] [Related]

  • 10. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
    Hancox JC, McPate MJ, El Harchi A, Zhang YH.
    Pharmacol Ther; 2008 Aug 01; 119(2):118-32. PubMed ID: 18616963
    [Abstract] [Full Text] [Related]

  • 11. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
    Towart R, Linders JT, Hermans AN, Rohrbacher J, van der Linde HJ, Ercken M, Cik M, Roevens P, Teisman A, Gallacher DJ.
    J Pharmacol Toxicol Methods; 2009 Aug 01; 60(1):1-10. PubMed ID: 19439185
    [Abstract] [Full Text] [Related]

  • 12. A history of the role of the hERG channel in cardiac risk assessment.
    Rampe D, Brown AM.
    J Pharmacol Toxicol Methods; 2013 Aug 01; 68(1):13-22. PubMed ID: 23538024
    [Abstract] [Full Text] [Related]

  • 13. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.
    Hoffmann P, Warner B.
    J Pharmacol Toxicol Methods; 2006 Aug 01; 53(2):87-105. PubMed ID: 16289936
    [Abstract] [Full Text] [Related]

  • 14. Effects of fluoroquinolones on HERG channels and on pancreatic beta-cell ATP-sensitive K+ channels.
    Zünkler BJ, Claassen S, Wos-Maganga M, Rustenbeck I, Holzgrabe U.
    Toxicology; 2006 Dec 07; 228(2-3):239-48. PubMed ID: 17027138
    [Abstract] [Full Text] [Related]

  • 15. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
    Thomas D, Karle CA, Kiehn J.
    Curr Pharm Des; 2006 Dec 07; 12(18):2271-83. PubMed ID: 16787254
    [Abstract] [Full Text] [Related]

  • 16. Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.
    Marostica E, Van Ammel K, Teisman A, Boussery K, Van Bocxlaer J, De Ridder F, Gallacher D, Vermeulen A.
    J Pharmacokinet Pharmacodyn; 2015 Dec 07; 42(6):659-79. PubMed ID: 26259721
    [Abstract] [Full Text] [Related]

  • 17. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
    Gintant GA, Su Z, Martin RL, Cox BF.
    Toxicol Pathol; 2006 Dec 07; 34(1):81-90. PubMed ID: 16507548
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656.
    Luo T, Luo A, Liu M, Liu X.
    Anesth Analg; 2008 Apr 07; 106(4):1161-70, table of contents. PubMed ID: 18349188
    [Abstract] [Full Text] [Related]

  • 19. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
    Polak S, Wiśniowska B, Brandys J.
    J Appl Toxicol; 2009 Apr 07; 29(3):183-206. PubMed ID: 18988205
    [Abstract] [Full Text] [Related]

  • 20. BeKm-1, a peptide inhibitor of human ether-a-go-go-related gene potassium currents, prolongs QTc intervals in isolated rabbit heart.
    Qu Y, Fang M, Gao B, Chui RW, Vargas HM.
    J Pharmacol Exp Ther; 2011 Apr 07; 337(1):2-8. PubMed ID: 21205913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.